Selective determination of tobacco-specific nitrosamines in mainstream cigarette smoke by GC coupled to positive chemical ionization triple quadrupole MS.

A rapid method for the selective determination of four kinds of tobacco-specific nitrosamines, N-nitrosonornicotine, N-nitrosoanatabine, N-nitrosoanabasine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, in mainstream cigarette smoke was developed by GC coupled to positive chemical ionization triple-quadrupole MS. After mainstream cigarette smoke was collected on a cambridge filter pad, the particulate matter was extracted with 0.1 M HCL aqueous solution, cleaned by positive cation-exchange solid extraction, and finally injected into GC-MS/MS using isotopically labeled analogues as internal standards. Excellent linearity was obtained over the concentration range of 0.5-200.0 ng mL(-1) for all tobacco-specific nitrosamines with values for correlation coefficient between 0.9996-0.9999. Limits of detection of each tobacco specific nitrosamine varied from 0.023-0.028 ng cig(-1), and lower limits of quantification varied from 0.077-0.093 ng cig(-1). The recovery of each tobacco specific nitrosamine was from 90.0-109.0%. The relative standard deviations of the intra-day and inter-day precisions were 3.1-5.8 and 3.9-6.6, respectively. This method was applied to reference and domestic cigarettes. The result showed that the method was consistent with traditional methods and can be used as an effective approach for the routine analysis of tobacco-specific nitrosamines.

The application of hepatic P450 reductase null gpt delta mice in studying the role of hepatic P450 in genotoxic carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mutagenesis.

The cytochrome P450 (P450 or CYP) is involved in both detoxification and metabolic activation of many carcinogens. In order to identify the role of hepatic P450 in the mutagenesis of genotoxic carcinogens, we generated a novel hepatic P450 reductase null (HRN) gpt delta mouse model, which lacks functional hepatic P450 on a gpt delta mouse background. In this study, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was used to treat HRN gpt delta mice and control littermates. Gene mutations in the liver and lungs were detected, and mutation spectra were analyzed. Pharmacokinetic analyses were performed, and tissue levels of NNK and metabolite were determined. NNK-induced mutant frequencies (MFs) were equivalent to spontaneous MFs in the liver, but increased more than 3 times in the lungs of HRN gpt delta mice compared to control mice. NNK-induced mutation spectra showed no difference between HRN gpt delta mice and control littermates. Toxicokinetic studies revealed reduced clearance of NNK with elevated tissue concentrations in HRN gpt delta mice. To our knowledge, these are the first data demonstrating that NNK cannot induce mutagenesis in the liver without P450 metabolic activation, but can induce mutagenesis in lungs by a hepatic P450-independent mechanism. Moreover, our data show that hepatic P450 plays a major role in the systemic clearance of NNK, thereby protecting the lungs against NNK-induced mutagenesis. Our model will be useful in establishing the role of hepatic versus extrahepatic P450-mediated mutagenesis, and the relative contributions of P450 compared to other biotransformation enzymes in the genotoxic carcinogens' activation.

Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry.

The dopamine level in the brain and the mesolimbick dopaminergic system are responsible for nicotine addiction. In the present study, extracellular dopamine in nucleus accumbens was collected by a brain microdialysis technique. Also a sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method with a gradient elution procedure was developed for a precise determination of dopamine in brain dialysate. The retention time of dopamine was about 11.32 min. The linear range was 20 - 1000 pg/mL. The limit of detection (LOD) and the limit of qualification (LOQ) were 5 and 20 pg/mL, respectively. The recovery ranged from 98.2 to 109.0%, and both the intra-RSD and inter-RSD were below <9%, respectively. The probe recovery for dopamine in this brain microdialysis experiment was about 25%. Finally, the dopamine concentrations in the rat brain microdialysates were determined, and the pharmacokinetics of extracellular dopamine in the brain nucleus accumbens after an intravenous injection of nicotine was successfully evaluated.